R&D channel feed – Endpoints News

R&D channel feed

As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval

6 years ago

Halozyme's lead drug flops in PhIII, forcing CEO to ax 160 and reset focus on tech platform

6 years ago

Worthless? Short attack on FibroGen claims their anemia drug roxa has a lethal Achilles’ heel — and it’s going down

6 years ago

Novo dumps proposed Rybelsus successor for newer model

6 years ago

Data suggest gene, cell therapy trial initiations in Europe lag behind North America — here's why

6 years ago

Eight years after a landmark buyout, Sanofi agrees to pay aggrieved Genzyme shareholders $315M to settle foot-dragging claims

6 years ago

Paratek's top antibiotic fails to clear a key competitive hurdle in head-to-head studies

6 years ago

Novartis' Cosentyx misses main goal in head-to-head trial with AbbVie's Humira

6 years ago

Sanofi's oncology R&D group marks a pair of setbacks on isatuximab/Libtayo combo as cancer studies fizzle out

6 years ago

Astellas rejoins the autoimmune antibody craze with Pandion partnership

6 years ago

Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to cell therapy 2.0

6 years ago

Merck's last crack at salvaging a $2.5B jury verdict in hep C patent showdown is shot down by appeals court

6 years ago

Neuroscience biotech led by former Pfizer crew wins $17M to target toxic tau

6 years ago

A RIP1 contender fails to make the cut at GSK after a fast fizzle in pancreatic cancer

6 years ago

Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?

6 years ago

Peter Hecht’s Ironwood spinout fails back-to-back studies on a key drug, crushing shares and triggering cutbacks — but he still sees a path forward

6 years ago

Catalyst Pharma's Firdapse bet on congenital myasthenic syndromes turns sour

6 years ago

Amgen is joining the biopharma exodus out of neurosciences R&D, cutting 180 R&D jobs in reorganization

6 years ago

Hey, wait up Amgen and Mirati, Boehringer Ingelheim is joining the KRAS crowd as early success inspires rivals

6 years ago

TG Therapeutics touts safer PI3Kδ inhibitor as execs tout PhII data, hunt quick OK for a tough niche

6 years ago

GSK team clinches positive trial for the first potential new TB vaccine in a century — with millions of lives at stake

6 years ago

Novartis' $111M bet on IL-17C drug turns sour — but MorphoSys, Galapagos will explore options

6 years ago

Atlas, Novo-backed biotech reels in ex-Nimbus CEO Don Nicholson as exec chairman, hooks $50M to conquer anemia

6 years ago

Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen?

6 years ago

First page Previous page 225 226 227228229 230 231 Next page Last page